Oral PCSK9 to drop LDL levels low

Published On 2021-12-06T17:50:17+05:30 | Updated On 6 Dec 2021 12:20 PM GMT

Overview

Low-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits within arteries, reducing or blocking blood flow thereby causing ischemic strokes and heart attacks. PCSK9 inhibitors work by a mechanism of blocking a liver protein that helps to destroy LDL cholesterol receptors on the surface of cells.

The PCSK9 protein is an important regulator of circulating LDL‐C levels, through its inhibitory action on recycling of the LDL receptor (LDLR). PCSK9 inhibition thus offers a novel therapeutic mechanism for the lowering of LDL‐C levels.

For more details, check out the full story on the link below:

Oral PCSK9 Inhibitor May Significantly Reduce LDL C Levels: DALLAS, The First Human Trial

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751